Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold

Gyre Therapeutics (NASDAQ:GYRE) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other analysts have also weighed in on GYRE. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Trading Down 3.2%

Shares of NASDAQ:GYRE opened at $7.55 on Friday. Gyre Therapeutics has a 12-month low of $6.11 and a 12-month high of $12.62. The stock has a 50 day moving average of $7.96 and a 200 day moving average of $7.78. The company has a market cap of $727.29 million, a PE ratio of 755.76 and a beta of 1.97.

Institutional Trading of Gyre Therapeutics

Institutional investors have recently modified their holdings of the company. State of Alaska Department of Revenue purchased a new position in shares of Gyre Therapeutics during the 3rd quarter valued at approximately $38,000. Bank of America Corp DE grew its position in Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after buying an additional 1,402 shares during the period. JPMorgan Chase & Co. increased its holdings in Gyre Therapeutics by 84.6% in the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after buying an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after acquiring an additional 3,244 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Gyre Therapeutics during the 4th quarter worth about $77,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.